CDK4 and cancer: These Rb-positive cancers may develop by overexpression or activation of cyclin D–CDK4/6, by loss of negative regulators of cyclin D-CDK4/6 (e.g., INK4A), or by oncogenic signaling pathways that activate cyclin D–CDK4/6 for cell proliferation [132–134].